Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells
Authors:
- 1 May 2001
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 15 (5) , 787-793
Abstract
Interleukin-2 (IL-2) is a growth factor which upon binding to high-affinity receptors (IL-2Rαβγ) triggers mitogenesis in T cells. IL-2Rα expression is restricted to T cells which have recently encountered antigen, and in healthy individuals the majority (>95%) of peripheral T cells are IL-2Rα negative. An aberrant expression of IL-2Rα has recently been described in cutaneous T-cell lymphoma (CTCL). Here, we study the regulation of IL-2Rα expression and STATs in a tumor cell line obtained from peripheral blood from a patient with Sezary syndrome (SS), a leukemic variant of CTCL. We show that (1) STAT3 (a transcription factor known to regulate IL-2Rα transcription) is constitutively tyrosine-phosphorylated in SS tumor cells, but not in non-malignant T cells; (2) STAT3 binds constitutively to a STAT-binding sequence in the promotor of the IL-2Rα gene; (3) the Janus kinase inhibitor, tyrphostine AG490, inhibits STAT3 activation, STAT3 DNA binding, and IL-2Rα mRNA and protein expression in parallel; and (4) tyrphostine AG490 inhibits IL-2 driven mitogenesis and triggers apoptosis in SS tumor cells. In conclusion, we provide the first example of a constitutive STAT3 activation in SS tumor cells. Moreover, our findings suggest that STAT3 activation might play an important role in the constitutive IL-2Rα expression, survival, and growth of malignant SS cells.Keywords
This publication has 25 references indexed in Scilit:
- Stat3 as an OncogeneCell, 1999
- Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cellsLeukemia, 1999
- The Jak-Stat Pathway: Cytokine Signalling from the Receptor to the NucleusJournal of Receptors and Signal Transduction, 1999
- Cytokine-Driven Immortalization of in vitro Activated Human T LymphocytesExperimental and Clinical Immunogenetics, 1998
- JAKS AND STATS: Biological ImplicationsAnnual Review of Immunology, 1998
- Histologic and Immunophenotypic Features Prior to Transformation in Patients with Transformed Cutaneous T-Cell LymphomaThe American Journal of Dermatopathology, 1998
- JAKs and STATs branch outTrends in Cell Biology, 1996
- Immunoregulatory Events in the Skin of Patients With Cutaneous T-Cell LymphomaArchives of Dermatology, 1996
- Leukemic T Cells from Patients with Cutaneous T-Cell Lymphoma Demonstrate Enhanced Activation Through CDw60, CD2, and CD28 Relative to Activation Through the T-Cell Antigen Receptor ComplexJournal of Investigative Dermatology, 1993
- Mycosis Fungoides in the United StatesJAMA, 1988